Oppenheimer Maintains Keros Therapeutics(KROS.US) With Buy Rating, Cuts Target Price to $63

Moomoo NewsDec 16 08:31 ET · Ratings

Oppenheimer Maintains Outperform on Keros Therapeutics, Lowers Price Target to $63

BenzingaDec 16 08:02 ET · Ratings

Keros Therapeutics Analyst Ratings

BenzingaDec 16 08:01 ET · Ratings

Analysts' Top Healthcare Picks: Aldeyra Therapeutics (ALDX), Keros Therapeutics (KROS)

TipRanksDec 16 07:50 ET · Ratings

Piper Sandler Maintains Keros Therapeutics(KROS.US) With Buy Rating, Cuts Target Price to $40

Moomoo NewsDec 16 07:31 ET · Ratings

Keros Therapeutics Cut to Neutral From Buy by Guggenheim

Dow JonesDec 16 05:28 ET · Ratings